In a report released yesterday, Mark Breidenbach from Oppenheimer maintained a Hold rating on Agios Pharma (AGIO). The company’s shares closed last Tuesday at $48.04.
According to TipRanks.com, Breidenbach is a 5-star analyst with an average return of 24.3% and a 51.0% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Arvinas Holding Company, and Iovance Biotherapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Agios Pharma with a $64.75 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $56.75 and a one-year low of $27.77. Currently, Agios Pharma has an average volume of 832.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
